iTolerance, Inc. Closes $17.1 Million Convertible Note Financing to Advance Development of Innovative Regenerative Medicines for Transplantation Without the Need for Life-Long Immunosuppression
The Company's proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel platform technology, iTOL-100, has demonstrated in animal models of Type 1 Diabetes the ability to induce local immune tolerance and allow long-term …
The Company's proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel platform technology, iTOL-100, has demonstrated in animal models of Type 1 Diabetes the ability to induce local immune tolerance and allow long-term engraftment of insulin-producing allogenic pancreatic islet cells without the need for chronic life-long immunosuppression
Lead program, iTOL-101, being developed as a potential breakthrough in curing Type 1 Diabetes
Second lead program, iTOL-102, is also being developed as another potential breakthrough in curing Type 1 Diabetes leveraging stem cell derived pancreatic islet
MIAMI, FL / ACCESSWIRE / March 21, 2022 / iTolerance, Inc. ("iTolerance" or the "Company"), an early stage regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, today announced the closing of its convertible note financing in which the Company raised a total of approximately $17.1 million in gross proceeds. The Company plans to use proceeds from the financing to translate the production of iTOL-100 from the academic labs to commercial manufacturing for use in its planned pre-clinical and clinical trials and for other general corporate purposes.
"As a start-up life sciences company, raising $17.1 million is a noteworthy endorsement from investors and bolsters our confidence in the potential of our proprietary platform technology. With this capital in hand, we are focused on executing next steps in de-risking our manufacturing processes and positioning ourselves to successfully advance into and through pre-clinical studies to support a Phase 1/2 clinical study for iTOL-101," commented Dr. Anthony Japour, Chief Executive Officer of iTolerance. "We believe our platform technology is a potential game changer for patients with Type 1 Diabetes and the physicians who treat them. Additionally, this technology can be applied to a number of cellular therapies for chronic conditions."
Lesen Sie auch
The Company's iTOL-100 platform technology is a biotechnology-derived Strepavidin-FasL fusion protein, a synthetic form of the naturally occurring protein FasL, mixed with a biotin-PEG microgel (SA-FasL microgel) that potentially allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression. In pre-clinical studies, iTOL-100 has been shown to establish durable, localized immune tolerance, allowing the implanted tissue, organoid or cell therapy to function as a replacement for damaged native cells.